ENGN
enGene Holdings Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.82
−0.75%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
Market Cap
$121.67M
MomentumView details →
1D Return
−0.75%
YTD Return
−79.79%
RSI (14)
49.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
Market Cap
$121.67M
RSI (14)
49.5
MomentumView details →
1D Return
−0.75%
YTD Return
−79.79%
SummaryUpdated Apr 1, 2026
enGene Holdings Inc. (NASDAQ:ENGN) is a clinical-stage biotechnology company founded in 2023 and based in Saint-Laurent, Canada. The company went public in February 2022 and operates through its subsidiary enGene, Inc. enGene focuses on developing genetic medicines delivered to mucosal tissues and other organs, representing a specialized approach within the broader gene therapy field. As a clinical-stage company, enGene has not yet generated revenue and is currently advancing its lead therapeutic candidate through clinical trials.
Similar companies
Latest newsMore news →
Richard Glickman resigned as director and chairman of the Board of Directors of enGene Therapeutics Inc., effective July 15, 2026.51d agoenGene Therapeutics Inc. reported its financial results for the second quarter of fiscal year 2026.81d agoenGene Therapeutics Inc. announced the resignation of Chief Medical Officer Hussein Sweiti effective June 14, 2026, and the termination of Chief Financial Officer Ryan Daws and Chief Legal Officer Lee Giguere effective July 15, 2026.82d ago